ubenimex has been researched along with Granulocytic Leukemia, Chronic in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, F; Fujisaki, T; Gondo, H; Niho, Y; Ohhinata, A; Okamura, T; Otsuka, T | 1 |
| Griffin, JD; Ikeda, Y; Kizaki, M; Miyakawa, Y; Sawafuji, K; Weisberg, E | 1 |
| Fujimaki, K; Ishigatsubo, Y; Kanamori, H; Koharazawa, H; Taguchi, J; Takabayashi, M; Takasaki, H; Yamaji, S | 1 |
| Abe, F; Fujii, H; Sukenaga, Y; Takeuchi, T; Yamada, M | 1 |
| Saito, Y; Uzuka, Y | 2 |
| Hiraoka, A; Masaoka, T; Shibata, H | 1 |
| Saito, Y; Usuka, Y | 1 |
| Im, T; Nakao, H; Oohira, H; Ota, K; Sannomiya, Y; Sasaki, A; Tatsumi, N; Yasui, Y | 1 |
1 trial(s) available for ubenimex and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Immunopotentiation with Ubenimex for prevention of leukemia relapse after allogeneic BMT. The Study Group of Ubenimex for BMT.
Topics: Adjuvants, Immunologic; Administration, Oral; Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Chronic Disease; Female; Graft vs Host Disease; Graft vs Host Reaction; Humans; Infant; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Recurrence | 1992 |
8 other study(ies) available for ubenimex and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Bestatin selectively suppresses the growth of leukemic stem/progenitor cells with BCR/ABL mRNA transcript in patients with chronic myelogeneous leukemia.
Topics: Cell Count; Cells, Cultured; Clone Cells; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukotriene C4; Protease Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Stem Cells | 2003 |
Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.
Topics: Aminopeptidases; Anti-Bacterial Agents; Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspases; Cell Division; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Activation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hydroxamic Acids; Imatinib Mesylate; K562 Cells; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinases; Phosphorylation; Piperazines; Protease Inhibitors; Pyrimidines; Serine; Signal Transduction | 2003 |
Long-term cytogenetic remission with ubenimex monotherapy in a case of chronic myeloid leukemia.
Topics: Aged; Bone Marrow Cells; Busulfan; Humans; Immunologic Factors; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Remission Induction; Time Factors | 2004 |
Purification and characterization of a ubenimex (Bestatin)-sensitive aminopeptidase B-like enzyme from K562 human chronic myeloid leukemia cells.
Topics: Amino Acid Sequence; Aminopeptidases; Cations, Divalent; Chlorides; Humans; Hydrogen-Ion Concentration; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Molecular Weight; Substrate Specificity; Tumor Cells, Cultured | 1994 |
[Bestatin therapy of chronic myelogenous leukemia].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Remission Induction; Survival Rate | 1993 |
Bestatin treatment of myelodysplastic syndromes and chronic myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Drug Therapy, Combination; Female; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes | 1991 |
Effects of ubenimex, a biological response modifier, on myelodysplastic syndrome and chronic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; Humans; Immunologic Factors; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes | 1991 |
[Combination therapy of chronic myelogenous leukemia with busulfan and bestatin].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Gene Rearrangement; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction | 1991 |